2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Sleep-Wake Disorder

Sleep-Wake Disorder

Parasomnias are potentially dangerous or harmful behaviors occurring during sleep-wake transitions, encompassing disorders like somnambulism, sleep terrors, nightmares, and REM sleep behavior disorder, and are categorized into REM-related, NREM-related, and other types.

References:

Sleep-Wake Disorder (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-A0134
    Isoflurane 26675-46-7 99.27%
    Isoflurane is a volatile anaesthetic. Isoflurane diminishs the effect of ROS activity. Isoflurane suppresses respiration. Isoflurane enables rapid anesthesia induction and emergence. Isoflurane protects against noise-induced hearing loss and tissue damage in mice. Isoflurane protects against renal ischemia and reperfusion injury and modulates leukocyte infiltration.
    Isoflurane
  • HY-113440
    5-Methoxytryptophol 712-09-4 99.95%
    5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
    5-Methoxytryptophol
  • HY-172412A
    Alixorexton enantiomer 2648350-16-5 99.42%
    Alixorexton (ALKS 2680) enantiomer is the enantiomer of Alixorexton (HY-172412). Alixorexton is a selective, orally active and brain-penetrant agonist for orexin-2 receptor and can be used for hypersomnias research.
    Alixorexton enantiomer
  • HY-P11633
    YLRPEGDW 99.43%
    YLRPEGDW is an orally active sleep-promoting peptide. YLRPEGDW upregulates Autophagy-related genes, increase Autophagy activity. YLRPEGDW could improve Caffeine-induced sleep reduction.
    YLRPEGDW
  • HY-P11632
    YLDLAPL 98.39%
    YLDLAPL is a sleep-enhancing peptide that can be isolated from truffle albumin hydrolysate. YLDLAPL exhibits sleep-promoting effects via regulation of lysosomal autophagy, neurological activity, tyrosine metabolism, and fatty acid elongation.
    YLDLAPL
  • HY-115304
    UCM 793 101374-18-9
    UCM 793 is a non-selective MT1/MT2 receptor agonist (pKis: 9.09 (MT1 receptor); 9.19 (MT2 receptor)). UCM793 increases the number of episodes and decreases the length of the episodes of wakefulness. UCM 793 influences quality of the vigilance states. UCM 793 decreases sleep onset without having an effect on NREM sleep maintenance.
    UCM 793
  • HY-B1504
    Acecarbromal 77-66-7
    Acecarbromal (Acetylcarbromal) is a Urea (HY-Y0271) derivative. Acecarbromal is a hypnotic and sedative agent.
    Acecarbromal
  • HY-106547
    Rilmazafone 99593-25-6
    Rilmazafone (450191S) is an orally active sleep inducer. Rilmazafone targets cytochrome P-450b and cytochrome P-450e. Rilmazafone induces hepatic drug-metabolizing enzyme activity in rats, mice and dogs. Rilmazafone is applicable for insomnia-related research.
    Rilmazafone